APA (7th ed.) Citation

Sohutskay, D., Tetrick, A., Goebel, W., Schwering, D., & Reddy, M. (2024). Preemptive Approach to Plerixafor Use Is Optimal in Patients With Relapsed/Refractory Germ Cell Tumors Undergoing Peripheral Blood Hematopoietic Stem Cell Collection: Effect on Collection Days, Yields, and Cost. Wiley. https://doi.org/10.1002/jca.22145

Chicago Style (17th ed.) Citation

Sohutskay, David O, Anne M Tetrick, W. Scott Goebel, Dave Schwering, and Manasa S Reddy. Preemptive Approach to Plerixafor Use Is Optimal in Patients With Relapsed/Refractory Germ Cell Tumors Undergoing Peripheral Blood Hematopoietic Stem Cell Collection: Effect on Collection Days, Yields, and Cost. Wiley, 2024. https://doi.org/10.1002/jca.22145.

MLA (9th ed.) Citation

Sohutskay, David O, et al. Preemptive Approach to Plerixafor Use Is Optimal in Patients With Relapsed/Refractory Germ Cell Tumors Undergoing Peripheral Blood Hematopoietic Stem Cell Collection: Effect on Collection Days, Yields, and Cost. Wiley, 2024. https://doi.org/10.1002/jca.22145.